Optimizing Vision Outcomes in nAMD

Optimizing Vision Outcomes in nAMD

ReachMD Healthcare Image

When time is vision, how can you address your patients’ fears and tailor therapy to achieve long-term success in the management of wet AMD?

  • Overview

    Age-related macular degeneration (AMD) is the most common cause of blindness in adults over the age of 50 years. Anti-VEGF therapy has markedly improved vision outcomes in patients with neovascular AMD, but what else can we do to maximize long-term vision in these patients? Drs. Do, Haller, and Singh discuss the key role of fluid in the treatment of wet AMD, dosing interval data from clinical trials, and the importance of patient expectations when selecting therapy.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free